"Biomarkers, Pharmacological" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Measurable biological parameters that serve for drug development, safety and dosing (DRUG MONITORING).
- Biomarkers, Pharmacological
- Pharmacological Biomarkers
- Biological Markers, Pharmacological
- Markers, Pharmacological Biological
- Pharmacological Biological Markers
Below are MeSH descriptors whose meaning is more general than "Biomarkers, Pharmacological".
Below are MeSH descriptors whose meaning is more specific than "Biomarkers, Pharmacological".
This graph shows the total number of publications written about "Biomarkers, Pharmacological" by people in Harvard Catalyst Profiles by year, and whether "Biomarkers, Pharmacological" was a major or minor topic of these publication.
To see the data from this visualization as text, click here.
|Year||Major Topic||Minor Topic||Total|
Below are the most recent publications written about "Biomarkers, Pharmacological" by people in Profiles.
Massively parallel pooled screening reveals genomic determinants of nanoparticle delivery. Science. 2022 07 22; 377(6604):eabm5551.
Muscle microRNAs in the cerebrospinal fluid predict clinical response to nusinersen therapy in type II and type III spinal muscular atrophy patients. Eur J Neurol. 2022 08; 29(8):2420-2430.
TISMO: syngeneic mouse tumor database to model tumor immunity and immunotherapy response. Nucleic Acids Res. 2022 01 07; 50(D1):D1391-D1397.
Fulfilling the Mandate of the US Food and Drug Administration's Accelerated Approval Pathway: The Need for Reforms. JAMA Intern Med. 2021 10 01; 181(10):1275-1276.
Systems analysis of miRNA biomarkers to inform drug safety. Arch Toxicol. 2021 Nov; 95(11):3475-3495.
Modulation of the effects of class Ib antiarrhythmics on cardiac NaV1.5-encoded channels by accessory NaVß subunits. JCI Insight. 2021 08 09; 6(15).
Assessment of tumor hypoxia and perfusion in recurrent glioblastoma following bevacizumab failure using MRI and 18F-FMISO PET. Sci Rep. 2021 04 07; 11(1):7632.
A Combination of Epigenetic BET and CDK9 Inhibitors for Treatment of Human Melanoma. J Invest Dermatol. 2021 09; 141(9):2238-2249.e12.
Inclusion of genetic variants in an ensemble of gradient boosting decision trees does not improve the prediction of citalopram treatment response. Sci Rep. 2021 02 12; 11(1):3780.
PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nat Rev Clin Oncol. 2021 06; 18(6):345-362.